The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1720
ISSUE 1720
January 20, 2025
Issue 1720
- Valeda Light Delivery System for Age-Related Macular Degeneration
- Emrosi — Low-Dose, Biphasic Oral Minocycline for Rosacea
- Dupilumab (Dupixent) for COPD
- Seladelpar (Livdelzi) for Primary Biliary Cholangitis
- Zenocutuzumab (Bizengri) for NSCLC and Pancreatic Adenocarcinoma
- Zanidatamab (Ziihera) for Biliary Tract Cancer (online only)
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Valeda Light Delivery System for Age-Related Macular Degeneration
January 20, 2025 (Issue: 1720)
The FDA has authorized use of the Valeda Light
Delivery System (LumiThera), a multiwavelength
photobiomodulation (PBM) device, to improve visual
acuity in patients with dry age-related macular
degeneration (AMD) who have best-corrected...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.